Stifel Downgrades Threshold Pharmaceuticals (THLD) to Hold

Go back to Stifel Downgrades Threshold Pharmaceuticals (THLD) to Hold

Cowen Downgrades Threshold Pharmaceuticals (THLD) to Market Perform

December 7, 2015 9:38 AM EST

Cowen downgraded Threshold Pharmaceuticals (NASDAQ: THLD) from Outperform to Market Perform.

Analyst Eric Schmidt commented, "Threshold and partner Merck KGaA announced that neither of evofosfamide's pivotal trials in pancreatic cancer or sarcoma met its primary OS endpoint. The results are disappointing, and... More

Threshold Pharma (THLD) Says Evofosfamide Studies Did Not Meet Primary Endpoints

December 7, 2015 6:18 AM EST

Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced the outcomes of two Phase 3 cancer studies (MAESTRO and TH-CR-406/SARC021) of evofosfamide (previously known as TH-302), an investigational hypoxia-activated prodrug, which is being evaluated for first-line treatment of advanced pancreatic adenocarcinoma and advanced soft tissue sarcoma, in combination with chemotherapy. The Phase 3 studies are being conducted under Threshold's collaboration with Merck KGaA, Darmstadt, Germany.

In the Phase 3 MAESTRO study, patients with previously untreated, locally advanced unresectable or metastatic pancreatic... More